Brief: Veracyte Inc - New Data To Be Presented At Asco 2022 Showing Immunoscore IC Assay's Ability To Identify Patients With Nsclc Who May Benefit From Icis
27/05/2022 24:53
May 26 (Reuters) - Veracyte Inc VCYT.O :
* VERACYTE INC - NEW DATA TO BE PRESENTED AT ASCO 2022
SHOWING
IMMUNOSCORE IC ASSAY'S ABILITY TO IDENTIFY PATIENTS WITH NSCLC
WHO MAY BENEFIT FROM ICIS
Source text for Eikon: ID:nBw5KN2sta
Further company coverage: VCYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina